[국제경영전략] 녹십자(영문)
- 등록일 / 수정일
- 페이지 / 형식
- 자료평가
- 구매가격
- 2010.08.07 / 2019.12.24
- 8페이지 / docx (MS워드 2007이상)
- 평가한 분이 없습니다. (구매금액의 3%지급)
- 1,100원
최대 20페이지까지 미리보기 서비스를 제공합니다.
자료평가하면 구매금액의 3%지급!
1
2
3
4
5
6
7
8
추천 연관자료
- 목차
-
1. Introduction
- The prospect of BT industry
- Case Study: A fresh outbreak of H1N1 pandemic
- Vaccine market overview
2. Analysis
- Green Cross in the Vaccine market
- SWOT analysis
- External analysis: competitors
- Strategies
3. Conclusion and References
- Future plans based on its core competence
- 본문내용
-
◎ Green Cross in the vaccine market
Green Cross is a R&D-oriented company that leads the Korean biotechnology industry since its foundation in 1967. Starting from the nation's first production and sales of Plasma Fractions in 1970, which required sophisticated technology, Green Cross has striven to develop ethical drugs that are hard to produce but essential to patients. Subsequently, it is now an internationally recognized biotechnology company in the fields of plasma fractions and vaccine.
In 2009, the only vaccine specialized factory in Korea, ‘Hwasun factory’ was completed. Total 67 million dollars was invested in the factory and the maximum annual production is 50 million doses. The annual demand of flu-vaccine is 15 million doses on average.
◎ SWOT analysis
Green Cross has accumulated a technological know-how of vaccine production. For example, it has developed a world’s second chickenpox vaccine. Its early mover advantage on the vaccine is a entry barrier itself. And it also has its own R&D institutes such as Mogam Biotechnology Research Institute.
Green Cross is relying on the ETC and specialty medicine which cannot guarantee the total market share. In other words, it is too risky to keep its sales for a long time only with these few ETC and specialty medicines.
- Vista of Mogam Biotechnology Research Institute and researcher (R&D capability)
The reason why Korea shows low self-sufficiency of vaccine is because importing from overseas is more profitable than starting vaccine business by oneself. Since it has strong competence in vaccine production, Green Cross should be successful.
A stable supplying of eggs is a crucial for the vaccine production process because it is a raw material for the vaccine. But only clean fertilized eggs can be used to make vaccines. There are not many poultry farms that produce this kind of eggs and moreover it takes more than 8 months to get them. So this is one of the
- 참고문헌
-
1. 바이오인 - http://www.bioin.or.kr/
2. LG 투자증권 이승호 연구원 분석 리포트 - http://www.greencross.com/
자료평가
-
아직 평가한 내용이 없습니다.
오늘 본 자료
더보기
최근 판매 자료
- [경영]페덱스 서비스경영
- [경영전략] 마이클 포터의 5 Force모델에 따른 미스터피자 분석
- 신제품 개발 성공사례와 개인적인 견해 (개념, 조건, 과정)
- [경영사례 분석]PDG세대를 겨냥한 감성 마케팅, 텐바이텐
- [e비즈니스]인터넷쇼핑몰 `텐바이텐` 마케팅전략 및 성공요인 분석(A+리포트)
- [특수마케팅이론과 사례] 유통마케팅-감성으로 말하는 텐바이텐 10x10 사례분석
- GATT 및 WTO체제의 비교분석
- 인적자원관리_성공한 기업의 모집과 선발에 대해 사례를 조사하고 시사점을 제시하세요
- 아모레퍼시픽 STP분석
- 아모레퍼시픽 마케팅 SWOT,STP,4P전략 분석 및 아모레퍼시픽 향후 마케팅전략 방향 제시 - 아모레퍼시픽 마케팅 연구
저작권 관련 사항 정보 및 게시물 내용의 진실성에 대하여 레포트샵은 보증하지 아니하며, 해당 정보 및 게시물의 저작권과 기타 법적 책임은 자료 등록자에게 있습니다. 위 정보 및 게시물 내용의 불법적 이용, 무단 전재·배포는 금지됩니다. 저작권침해, 명예훼손 등 분쟁요소 발견시 고객센터에 신고해 주시기 바랍니다.